Comparison of the effect of bezafibrate on improvement of atherogenic lipoproteins in Japanese familial combined hyperlipidemic patients with or without impaired glucose tolerance

Cardiovascular Drugs and Therapy

Volumn 12, Issue 1, 1998, Pages 3-12

  Hayashi, Kozo ^a   Kurushima, Hitoshi ^a   Kuga, Yoshio ^a   Shingu, Tetsuji ^a   Tanaka, Kouichi ^a   Yasunobu, Yuji ^a   Nomura, Katsuhiko ^a   Ohtani, Harumi ^a   Hiraga, Takaki ^a   Toyota, Yasushi ^a   Katano, Takahiro ^a   Sakai Ohta, Kazuko ^a   Kajiyama, Goro ^a  

^a HIROSHIMA UNIV SCHOOL OF MEDICINE   (Japan)

Author keywords

Apolipoprotein B gene polymorphism; Bezafibrate; Cholesteryl ester transfer protein; Familial combined hyperlipidemia; Impaired glucose tolerance; LDL subclass; Lipoprotein lipase

Indexed keywords

APOLIPOPROTEIN B; BEZAFIBRATE; CHOLESTEROL ESTER TRANSFER PROTEIN; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN; LIPOPROTEIN LIPASE; LOW DENSITY LIPOPROTEIN; SIGNAL PEPTIDE; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; ATHEROGENESIS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; ENZYME ACTIVITY; FAMILIAL HYPERLIPEMIA; FEMALE; GENETIC POLYMORPHISM; HUMAN; IMPAIRED GLUCOSE TOLERANCE; LIPOPROTEIN BLOOD LEVEL; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; ANTILIPEMIC AGENTS; APOLIPOPROTEINS B; BEZAFIBRATE; CARRIER PROTEINS; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL ESTERS; FEMALE; GLUCOSE TOLERANCE TEST; GLYCOPROTEINS; HUMANS; HYPERLIPIDEMIA, FAMILIAL COMBINED; LIPOPROTEIN LIPASE; LIPOPROTEINS; LIPOPROTEINS, LDL; MALE; MIDDLE AGED;

EID: 15444352746     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1007781310827     Document Type: Article

References (48)

1. Krauss RM. Heterogeneity of plasma low-density lipoproteins and atherosclerosis risk. Curr Opin Lipidol 1994;5: 339-349.
2. Krauss RM, Kesaniemi A. Dyslipidemic syndromes and atherosclerosis: Recent advances and challenges for the future. Curr Opin Lipidol 1995;6:187-189.
3. Gardner CD, Fortman SP, Krauss RM. Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. JAMA 1996;276: 875-881.
4. Stampfer MJ, Krauss RM, Ma J, Blanche PJ, Holl LG, Sacks FM, Hennekens CH. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA 1996;276:882-888.
5. Austin MA, Brunzell JD, Fitch WL, Krauss RM. Inheritance of low density lipoprotein subclass patterns in familial combined hyperlipidemia. Arteriosclerosis 1990;10:520-530.
6. Eisenberg S, Gavish D, Oschry Y, Fainaru M, Deckelbaum RJ. Abnormalities in very low, low, and high density lipoproteins in hypertriglyceridemia. Reversal toward normal with bezafibrate treatment. J Clin Invest 1984;74:470-482.
7. Gavish D, Oschry Y, Fainaru M, Eisenberg S. Changes in very low-, low-, and high-density lipoproteins during lipid lowering (bezafibrate) therapy: Studies in type Ila and type Ilb hyperlipoproteinemia. Eur J Clin Invest 1986;16:61-68.
8. Vessby B, Lithell H. Interruption of long-term lipid-lowering treatment with bezafibrate in hyperlipidemic patients. Effects on lipoprotein composition, lipase activities and the plasma fatty acid spectrum. Atherosclerosis 1990;82: 137-143.
9. Packard CJ, Clegg RJ, Dominiczak MH, Lorimer AR, Shepherd J. Fffects of bezafibrate on apolipoprotein B metabolism in type III hyperlipoproteinemic subjects. J Lipid Res 1986:27:930-938.
10. Grundy SM, Vega GL. Fibric acids: Effects on lipids and lipoprotein metabolism. Am J Med 1987;83:9-20.
11. Shepherd J. Mechanism of action of fibrates. Postgrad Med J 1993;69:34-41.
12. Homma Y, Ozawa H, Kobayashi T, Yamaguchi H, Sakane H, Mikami Y, Mikami Y, Nakamura H. Effects of bezafibrate therapy on subfractions of plasma low-density lipoprotein and high-density lipoprotein, and on activities of lecithin:cholesterol acyltransferase and cholesteryl ester transfer protein in patients with hyperlipoproteinemia. Atherosclerosis 1994;106:191-201.
13. Ericsson C-G, Hamsten A, Nilsson J, Grip L, Svane B, Faire U. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet 1996;347:849-853.
14. Singh ATK, Rainwater DL, Haffner SM, Van de Berg JL, Shelledy WR, Moore PH, Dyer TD. Effect of diabetes on lipoprotein size. Arterioscler Thromb Vasc Biol 1995;15: 1805-1811.
15. Austin MA, Mykkanenn L, Kuusisto J, Edwards KL, Nelson C, Haffner SM, Pyorola K, Laakso M. Prospective study of small LDLs as a risk factor for non-insulin dependent diabetes mellitus in elderly men and women. Circulation 1995;92:1770-1778.
16. Boerwinkle E, Lee SS, Butler R, Schumaker VN, Chan L. Rapid typing of apolipoprotein B DNA polymorphisms by DNA amplification. Atherosclerosis 1990;81:225-232.
17. Berg K, Hames C, Hahlen G, Frick MH, Krishan I. Genetic variation in serum low density lipoproteins and lipid levels in man. Proc Natl Acad Sci USA 1976;73:937-940.
18. Tikkanen MJ, Bilkari J, Akerblom HK, Pesonen E. Apolipoprotein B polymorphism associated with altered apolipoprotein B and low-density lipoprotein cholesterol levels in Finnish children. Br Med J 1988;296:169-170.
19. Soria LF, Ludwig EH, Clarke HRG, Vega GL, Grundy SM, McCarthy BJ. Association between a specific apolipoprotein B mutation and familial defective apolipoprotein B-100. Proc Natl Acad Sci USA 1989;86:587-591.
20. Kane JP, Havel RJ. Disorders of the biogenesis and secretion of lipoproteins containing the B apolipoproteins. In: Scriver CR et al., eds. The Metabolic and Molecular Bases on Inherited Disease, 7th ed. New York: McGraw-Hill, 1995: 1853-1885.
21. Austin MA, Breslow JL, Hennekens CH, Buring JE, Willett WC, Krauss RM. Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA 1988;260: 1917-1921.
22. Krauss RM, Burke DJ. Identification of multiple subclasses of plasma low-density lipoproteins in normal humans. J Lipid Res 1982;23:97-104.
23. Summary of the second report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel II). JAMA 1993;269:3015-3023.
24. Hayashi K, Ohtani H, Kurushima H, Nomura S, Koide K, Kunita T, Tanaka K, Yasunobu Y, Kambe M, Kajiyama G. Decreases in plasma lipid content and thorombotic activity by ethyl icosapentate purified from fish oils. Curr Ther Res 1995;56:24-31.
25. Hayashi K. Ohtani H, Okura Y, Tanaka K, Yasunobu Y, Mizuno T, Fujima M, Kambe M, Kajiyama G. Hypolipidemic effect of beraprost sodium in patients with arteriosclerosis obliterans accompanied by hyperlipidemia. Curr Ther Res 1994;55:1486-1491.
26. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of the preparative centrifuge. Clin Chem 1972;18:499-502.
27. Murase T, Uchimura H. A selective decline of postheparin plasma hepatic triglyceride lipase in hypothyroid rates. Metabolism 1980;29:797-801.
28. Yamada N, Murase T, Akanuma Y. Itakura H, Kosaka K. A selective deficiency of hepatic triacylglycerol lipase in guinea pigs. Biochim Biophys Acta 1979;575:128-134.
29. Hayashi K, Dojo Y, Hirata Y, Ohtani H, Nakashima K, Nishio E, Kurushima H, Saeki M, Kajiyama G. Metabolic changes in LDL receptors and an appearance of scavenger receptors after phorbol ester-induced differentiation of U937 cells. Biochim Biophys Acta 1991;1082:152-160.
30. Kurushima H, Hayashi K, Toyota Y, Kambe M, Kajiyama G. Comparison of hypocholesterolemic effects induced by dietary linoleic acid and oleic acid in harmsters. Atherosclerosis 1995;114:213-221.
31. Castelli WP, Garrison RJ, Wilson PWF, Abbott RD, Kalousdian S, Kannel WB. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham study. JAMA 1986;256:2835-2838.
32. Manninen V, Huttunen JK, Heinonen OP, Tenkanen L, Frick MH. Relation between baseline lipid and lipoprotein value and the incidence of coronary heart disease in the Helsinki heart study. Am J Cardiol 1989;63:42H-47H.
33. Brown G, Albers JJ, Fisher LD, Schaefer SM, Lin JT, Kaplan C, Zhao XQ, Bisson RD, Fitzpatrick VF, Dodge HT. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990;323:1289-1298.
34. The Multiple Risk Factor Intervention Trial Research Group. Mortality rates after 10.5 years for participants in the Multiple Risk Factor Intervension Trial. JAMA 1990;263:1795-1801.
35. The Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-1389.
36. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW, McKillop JH, Packard CJ. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-1307.
37. Tribble DL, van den Berg JJM, Motchnik PA, Ames BN, Lewis DM, Chait DM, Krauss RM. Oxidative susceptibility of low density lipoprotein subfractions is related to their ubiquinol-10 and alpha-tocopherol content. Proc Natl Acad Sci USA 1994;91:1183-1187.
38. Krauss RM, Lindgren FT, Williams PT, Kelsey SF, Brensike J, Vranizan K, Detre KM, Levy RI. Intermediate-density lipoproteins and progression of coronary artery disease in hypercholesterolemic men. Lancet 1987;2:62-66.
39. Phillips NR, Waters D, Havel RJ. Plasma lipoproteins and progression of coronary artery disease evaluated by angiography and clinical events. Circulation 1993;88:2762-2770.
40. Rapp JH, Lespine A, Hamilton RL, Colyvas N, Chaumeton AH, Tweedie-Hardman J, Kotite L, Kunitake ST, Havel RJ, Kane JP. Triglyceride-rich lipoproteins isolated by selected-affinity anti-apolipoprotein B immunosorption from human atherosclerotic plaques. Arterioscler Thromb 1994;14: 1767-1774.
41. Zilversmit DB. Atherogenic nature of triglycerides, postprandial lipidemia, and triglyceride-rich remnant lipoproteins. Clin Chem 1995;41:153-158.
42. Guerin M, Bruckert E, Dolphin PJ, Turpin G, Chapman MJ. Fenofibrate reduces plasma cholesteryl ester transfer from HDL to VLDL and normalizes the atherogenic, dense LDL profile in combined hyperlipidemia. Arterioscler Thromb Vasc Biol 1996;16:763-772.
43. Rauh G, Schuster H, Muller B, Schewe S, Keller C, Wolfram G, Zollner N. Genetic evidence for 7 families that the apolipoprotein B gene is not involved in familial combined hyperlipidemia. Atherosclerosis 1990;83:81-87.
44. Berndt J, Gaumert R, Still J. Mode of action of the lipid lowering agents clofibrate and BM 15075 on cholesterol biosynthesis in rat liver. Atherosclerosis 1978;30:147-152.
45. Jiao S, Matsuzawa Y, Matsubara K, Kihara S, Nakamura T, Tokunaga K, Kubo M, Tarui S. Increased activity of intestinal acyl-coA:cholesterol acyltransferase in rats with streptozotocin-induced diabetes and restoration by insulin supplementation. Diabetes 1988;37:342-346.
46. Jiao S, Moberly JB, Cole TG, Schonfeld G. Decreased activity of acyl-CoA:cholesterol acyltransferase by insulin in human intestinal cell line Caco-2. Diabetes 1989;38:604-609.
47. Olsson AG, Rossner S, Walldius G, Carlson LA, Lang PD. Effect of BM 15.075 on lipoprotein concentrations in different types of hyperlipoproteinaemia. Atherosclerosis 1977;27:279-287.
48. Austin MA. Plasma triglyceride and coronary heart disease. Arterioscler Thromb 1991;11:2-14.